2026 Addiction Treatment M&A Market Update

OLYMPIC M&A

2026 Addiction Treatment M&A Market Update

What Today’s Evidence Means for Addiction Treatment Business Owners Considering a Sale or Partnership.

Treatment need remains substantial. Your company’s readiness determines how that need translates into a credible acquisition opportunity.

For owners of addiction treatment businesses, the 2026 picture is specific: acquisitions continue, operating results vary, and reimbursement and compliance deserve close attention. Your options depend on the services you deliver and the evidence behind your earnings.

If you own a substance use disorder treatment business, these are the questions worth asking:

Which 2026 developments actually matter for a business like mine?
What can public transactions tell me about buyer interest and valuation?
How will my payer contracts, staffing and service mix hold up in diligence?
What should I address before discussing a sale or partnership?

Start with dated evidence, then apply it to your business.

This update covers U.S. addiction treatment services, including residential treatment, withdrawal management, intensive outpatient programs (IOP), partial hospitalization programs (PHP), and opioid treatment programs (OTPs). These models have different economics and approval requirements. A national headline rarely answers an individual owner’s questions.

The evidence below was available by October 12, 2026. The population survey covers civilian, noninstitutionalized people age 12 and older in 2025; the facility survey describes 2024. Company results identify their reporting periods. Transaction examples are selected public disclosures, not a complete deal census. Seller implications are our interpretation, and no full-year 2026 result is implied.

44.6M

People age 12+ with past-year substance use disorder in 2025

SAMHSA, 2025 NSDUH; released July 2026

11.0%

Share of people with past-year substance use disorder who received substance use treatment in 2025

SAMHSA, 2025 NSDUH, treatment estimates

15,953

Substance use treatment facilities responding to the 2024 national facility survey

SAMHSA, 2024 N-SUMHSS Annual Report

The treatment gap is an important public-health reality. It is not a count of prospective paying admissions. Geography, treatment preferences, coverage, referral access and appropriate clinical capacity determine the opportunity for an individual provider.

The Market Behind the Headlines

The 2025 NSDUH describes a large population with substance use disorder, including alcohol and drug use disorders that can overlap. It does not establish that everyone needs residential care, seeks treatment, or can access a particular provider. For a seller, a useful market analysis connects local need with actual referrals, admission criteria, authorized services and collections. The question is how reliably your organization converts appropriate access into care that is delivered, documented and paid.

There is also encouraging public-health progress. In its May 2026 release, CDC estimated 69,973 overdose deaths during 2025, about 14% below its then-current 2024 estimate. Those figures were provisional. Falling mortality neither eliminates treatment need nor establishes a revenue trend. Owners should resist a growth story built entirely around crisis statistics and instead explain what their own census, payer access and referral patterns show.

83.8%

Share of responding substance use facilities offering outpatient care in 2024. Residential care was offered by 22.5% and hospital inpatient care by 7.5%. These categories overlap. The figures help describe service delivery; they do not measure open capacity or acquisition targets.

SAMHSA, 2024 N-SUMHSS, Figure 2.2

$141.2M

Acadia’s comprehensive treatment center revenue in Q2 2026, versus $141.5 million a year earlier: approximately flat. It also opened two CTC locations that quarter. Expansion activity and revenue growth can move differently.

Acadia, quarter ended June 30, 2026; released July 28

Feb. 16

The 2026 compliance date for the updated federal Part 2 substance use disorder records rule has passed. Privacy policies, consent workflows and breach-response procedures belong in sale preparation now, including how information will be shared during diligence.

HHS Office for Civil Rights, Part 2 guidance

What Public Transactions Actually Show

Several disclosures demonstrate activity without establishing a marketwide boom. Bradford announced its acquisition of Parkdale Center in February 2026, adding a professionals-focused addiction and co-occurring treatment program. MKH’s portfolio identifies March 2026 as the start of its Haven Health Management investment; Haven spans addiction and mental-health services. MTS confirms CleanSlate’s sale to Spero Health, while Massachusetts records the associated notice received April 30. Notice receipt is not a closing date.

Selected Evidence Through the Current Research Cutoff

2025: Bradford/Texas → Feb. 2026: Parkdale → Mar.: MKH/Haven → Apr.: CleanSlate notice → July: Acadia results

The common thread is company-specific strategy, with different service models and transaction circumstances.

Sources: Bradford Texas announcement; Parkdale announcement; MKH portfolio; Massachusetts notice register; Acadia Q2 results.

These examples support a targeted buyer search. A professional-focused program, a mixed behavioral-health platform and an outpatient medication-treatment network are different acquisitions. None of the cited disclosures supplies a comparable EBITDA multiple for your company.

Operating evidence is similarly mixed. Acadia’s Q2 release reports an 8.4% decline in specialty-treatment revenue, partly related to facility closures. That category is broader than addiction treatment. Its results are a useful caution about execution and service mix, rather than a forecast for every independent treatment center.

What Makes an Addiction Treatment Business Assessable

A credible sale story gives a buyer enough evidence to test continuity, earnings and risk. Build a location-level picture rather than averaging away a weak program or one unusually favorable contract. Start with six areas:

Service mix and capacity: distinguish licensed beds or program slots from staffed, operational capacity and clinically appropriate utilization.
Collections: reconcile admissions, authorized days or visits, claims, denials, adjustments and cash by payer and service line.
Referral durability: identify concentration, channel economics and relationships that can continue when the founder steps back.
Workforce depth: document vacancies, turnover, contractor reliance, clinical supervision and the cost of replacing owner responsibilities.
Quality evidence: define retention, completion and follow-up measures consistently, including exclusions and the limits of your data.
Compliance: organize licensing, accreditation, payer audits, consent practices and referral arrangements. Resolve issues with appropriate advisers before promising a clean handoff.

Which buyer types could fit your model?

Addiction Treatment Operators

Existing addiction providers may value a complementary geography or care setting. Bradford’s acquisitions illustrate expansion through established programs; its needs are not a mandate to buy every available center.

Sponsor-Backed Platforms

A platform may seek operating depth and room to build. MKH/Haven illustrates a mixed addiction and mental-health investment. Confirm current capital availability, service priorities and integration capacity.

Outpatient Networks

Medication-treatment and outpatient organizations have distinct staffing, payer and geographic requirements. CleanSlate/Spero shows consolidation within that model; similarity alone does not establish fit or price.

Regional Partners

A regional operator or healthcare organization may have a local strategic rationale. Treat this as a buyer-search category to investigate, with financing, authority and actual appetite verified directly.

Buyer selection is a practical exercise: confirm the service model, geography, payer tolerance, financing and management plan. A long list of familiar healthcare names is less useful than a qualified group whose capabilities match the business and the owner’s priorities.

What Drives Value and Cash at Closing

There is no defensible universal 2026 addiction-treatment multiple in the primary sources reviewed here. Public-company trading measures, debt leverage and broad behavioral-health transaction ranges answer different questions. A useful valuation starts with sustainable earnings, service-specific comparable evidence where available, and buyer feedback. It also separates enterprise value from what the owner actually receives after debt, adjustments, transaction costs and retained risks.

Test the earnings before negotiating the headline.

A proposed owner-compensation add-back needs a corresponding estimate of replacement management and clinical costs. A revenue increase needs evidence of collectibility. A new location’s losses require a clear explanation of the spending needed to make that site operational.

Improved documentation can narrow uncertainty. It does not guarantee a higher price or make every adjustment acceptable.

Deal terms deserve equal attention. Read how working-capital adjustments affect a treatment-center sale before comparing proceeds, and examine earnout payment terms before treating contingent consideration as cash. If property is included, agree whether the operating business and real estate are being valued separately and which rent assumptions apply.

Protecting Care, Staff and Continuity

A transaction affects more than ownership.

Patients may depend on a consistent treatment team, location and medication-access process. Staff need clarity about reporting relationships and operating expectations. Referrers and payers need to know who is accountable after closing. These issues should inform buyer selection before exclusivity narrows your alternatives.

Translate concerns about culture into questions a buyer can answer and commitments counsel can evaluate:

Who will control clinical decisions, staffing budgets and changes to the services offered?
Which leaders and clinicians are expected to stay, and what funded retention or recruitment plan supports that expectation?
How will payer contracting, records access, billing and patient communications work during the transition?
What happened to comparable programs after this buyer’s previous acquisitions, and can those operators provide references?

For OTPs, ownership changes intersect with a specific federal framework. SAMHSA requires change-of-ownership notification to its Division of Pharmacologic Therapies or the relevant compliance officer. State, DEA, accreditation and payer requirements also need review. Build the transaction timetable around verified dependencies; avoid assuming existing approvals simply follow the purchase agreement.

Make the handoff concrete before signing.

Identify each required notice, consent or approval, its responsible party and the operating dependency it protects. Agree which matters must be resolved before closing and what happens if they are delayed. Our OTP ownership-transfer guide develops these questions for sellers of federally certified programs.

A documented transition plan supports accountability. It cannot eliminate every execution risk.

Choose the Outcome Before the Structure

A sale is one possible response to the market. Your goals should determine which alternatives deserve attention.

Stay independent while strengthening management, cash conversion and service-line reporting.
Consider a partnership with retained ownership after evaluating rollover equity rights and risks, including debt, dilution, control and uncertain future liquidity.
Plan a full transition with realistic leadership replacement, approval requirements and responsibilities after closing.
Obtain an informed assessment of readiness before deciding whether to approach buyers.

Preparation preserves choices.

For an IOP or PHP business, begin with outpatient addiction-treatment sale preparation. Review program economics, authorizations and staffing by location. That work is useful whether you pursue a transaction or continue operating independently.

The 2026 Policy Issues to Underwrite

Reimbursement requires program-level analysis. CMS publishes specific 2026 Medicare OTP payment bundles; they are national Medicare rates before locality adjustments, not a universal addiction-treatment fee schedule. The 2026 IOP rule likewise applies defined payment methods to eligible provider settings. Do not assume an independent outpatient license alone creates Medicare IOP billing eligibility. For your business, verify enrollment, covered services, authorizations, contracted rates and actual collections. A favorable policy headline should enter the financial model only when its applicability is established.

Access rules and enforcement are moving on different tracks. HHS and DEA extended qualifying telemedicine prescribing flexibilities through December 31, 2026; that is temporary federal authority, subject to other requirements, rather than a permanent 2027 operating assumption. On parity, DOL’s September 8, 2026 bulletin reaffirms nonenforcement of the new 2024-rule provisions while statutory obligations continue. It prioritizes treatment exclusions, medical-necessity reviews and network adequacy, including reimbursement methodologies. These priorities matter for access disputes, but they do not guarantee a provider rate increase or approval of a particular course of care.

Medicaid eligibility and confidentiality deserve coordinated planning. CMS’s June 2026 interim final rule generally requires states to implement community-engagement requirements by January 1, 2027, with specified exclusions, including certain people with substance use disorder and treatment participants. September 29 HHS guidance addresses use of protected substance use disorder records to verify exclusions. Avoid assuming either universal coverage loss or automatic protection. Review the relevant states, eligibility-support workflows, lawful information handling and potential collection delays with qualified advisers.

A practical preparation agenda for the months ahead:

Reconcile trailing financial performance with current census and subsequent cash collections.
Review payer terms, eligibility workflows and exposure to individual contracts or reimbursement changes.
Document operational, privacy and ownership-transfer dependencies with counsel and clinical leadership.
Separate existing capacity from expansion plans that still need staff, permissions or funding.
Test buyer financing and transition capabilities before granting exclusivity.

Use a base case and clearly identified downside scenarios rather than one optimistic forecast. Distinguish a documented rule from a proposal, and a reimbursement opportunity from revenue your organization is already entitled to collect. This report is transaction-planning information, not clinical, legal, tax or investment advice.

Your Next Step

We host a private, owner-only briefing covering exactly what’s in this report — and the specific steps you can take right now to protect your value and your options.

If you’re asking how to sell an addiction treatment business — or simply how to understand what yours is worth — this session is built for you. You’ll leave knowing:

What your addiction treatment business is worth in today’s market — and what’s driving or limiting that number
The three mistakes that cost addiction treatment owners real money — and how to avoid every one of them
What separates a premium business from a discounted one in the eyes of a sophisticated buyer
How to strengthen your position before any buyer approaches you — whether you transact in 12 months, 36 months, or never

This session is limited to 10 owners so Tony can answer your specific questions directly. It's a real conversation, not a presentation. Tony reads every question submitted before the session.

Limited to 10 owners per session | Confidential | No cost

Prefer a private conversation about your specific business first? Schedule a confidential strategy call.
Want a quick estimate of your company’s value? Use the behavioral-health business valuation calculator.

Send Me the Free Report

Delivered to your inbox immediately. No webinar. No sales call. No obligation.

No webinar. No sales call. No obligation. Just the most important market

intelligence available for concierge practice owners right now.

Frequently Asked Questions About Addiction Treatment M&A in 2026

Does the treatment gap prove my center can grow?

No. SAMHSA’s estimates show population-level need and treatment receipt. Growth depends on local access, clinically appropriate demand, staffing, payer coverage and referral relationships. Evaluate your actual admissions and collections; the national untreated population is not an addressable revenue forecast.

Are addiction treatment acquisitions happening in 2026?

Yes. Primary sources confirm Bradford/Parkdale, MKH’s Haven investment and CleanSlate’s sale to Spero. They involve different service models, and Haven includes mental-health services. These examples establish activity, not a complete transaction count or evidence that every buyer is acquiring.

What EBITDA multiple should an addiction treatment business owner expect?

The reviewed primary disclosures do not establish a reliable marketwide range. Compare service model, geography, earnings quality, size, payer mix and transaction structure before using a comparable. A company-specific assessment should make its assumptions and evidence explicit.

Which 2026 changes should sellers review first?

The applicable Part 2 compliance requirements, program-specific Medicare rules, year-end telemedicine planning and state Medicaid eligibility implementation deserve attention. Relevance depends on your services, payer exposure and states. Confirm the current requirements with qualified advisers before changing operations or forecasts.

Should I sell now or wait?

Start with your personal goals, operating performance and readiness. Compare the cost and risk of remaining independent with realistic transaction alternatives. Addressing reporting, management or approval gaps may improve the decision even when you choose not to sell.

About Tony Siebel

Tony Siebel is the Founder and Managing Director of Olympic M&A, a specialized concierge practice brokerage and advisory firm focused on helping concierge medicine physicians understand their options and maximize their outcomes.

As a concierge practice broker with direct experience on both sides of the transaction table, Tony brings a perspective no other advisor in this space can offer.

What makes Tony's perspective unique for concierge physicians — in the order that matters most:

The only M&A advisor in the country with direct experience acquiring concierge practices from inside the nation’s largest concierge network
Former MDVIP Corporate Development Director responsible for acquiring independent concierge practices nationally
Recruited and evaluated more than 60 concierge physicians nationwide
Advisor on $70M+ in completed healthcare M&A transactions

Tony has written extensively on healthcare consolidation, founder transitions, and strategic positioning in concierge medicine. Through Olympic M&A, he helps concierge physicians understand their options, protect what they have built, and structure partnerships that respect the physician-patient relationship.

OLYMPIC M&A